The NUS Academy for Healthy Longevity invites you to the Geromedicine Conference, set to take place from February 26-27, 2026, at the National University of Singapore. This premier event will gather global experts in geroscience, researchers, clinicians and industry leaders to explore the translation of geroscience

San Diego, CA – March 11–12, 2026 – Longevity Global will host the inaugural Longevity Innovation Forum, a two-day gathering bringing together leading scientists, clinicians, biotech founders, investors, and longevity enthusiasts advancing the science and translation of healthy aging. Held in San Diego’s thriving biotech hub,

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ER-100. The IND clearance allows Life Bio

Roatán, Honduras — Rejuve.AI is activating the International Longevity Research Database (IRLDB) through its first real-world study cohort at the Longevity Biomarkers Competition and Summit, taking place February to March 2026 as part of the Infinite Games in Roatán, Honduras. The IRLDB is being activated through

The Longevity World Forum announces its move to Madrid, reinforcing its international positioning with a new location aligned with its growth and leadership objectives in the field of longevity science and healthy ageing. The Spanish capital beats the cities that were postulated as possible venues for

Longevity Investors announces the upcoming Longevity Investors Lunch 2026, an exclusive, application-only gathering designed specifically for investors seeking exposure to the most compelling opportunities emerging at the intersection of longevity science, technology, and capital. Held during the World Economic Forum in Davos, the event convenes a

Why do we age at all, and why do different species age at such dramatically different rates? After decades of longevity research, biologists still disagree on the most basic questions: What is aging? Is it possible to stop or reverse it? And what strategies stand a

Cambridge, MA, USA – November 18, 2025: Vincere Biosciences today announced the receipt of a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutics Pipeline Program, which supports the advancement of promising therapies through preclinical and clinical stages. The

Nov 7, 2025 – Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules discovered using generative AI. Powered by Insilico’s proprietary end-to-end Pharma.AI platform, the portfolio covers

Spanning 350 square metres, the new Centre brings together state-of-the art facilities within an integrated multidisciplinary framework to enable clinical research and implementation of gerodiagnostics and gerotherapeutics, enhancing and optimising healthspan throughout the adult lifespan and setting new benchmarks for healthy longevity research and innovation. Singapore,

The Alliance for Longevity Science, Arts & Entertainment (ALSAE)—pronounced “all say”—today announced its official launch, pioneering a new nonprofit effort to accelerate progress against the chronic diseases of aging by bridging breakthroughs in longevity science with the transformative influence of arts and entertainment. Longevity science (sometimes called

HackAging.ai is the global online hackathon at the intersection of Agentic AI and longevity science, bringing together researchers, founders, and engineers to accelerate solutions that extend healthy human lifespan. Turn two weeks into a job, a useful tool, a collaboration, or a company. The event is

YouthBio Therapeutics, a biotechnology company pioneering partial cellular reprogramming to treat diseases of aging, today announced a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB002. In its formal response, the FDA agreed that existing preclinical data support the bioactivity of YB002 and

On September 18, 2025, Longevity Xplorer (LongX) will be hosting the first-ever “Youth in Longevity Biotech Showcase”, a virtual event featuring lightning talks from young professionals in longevity fellowships around the world. The event will cover fellow contributions and highlight the importance in supporting the next